Bepridil: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 19: | Line 19: | ||
| routes_of_administration = Oral | | routes_of_administration = Oral | ||
}} | }} | ||
__NOTOC__ | |||
{{CMG}} | |||
==Overview== | |||
'''Bepridil''' (trade name '''Vascor''') is a [[calcium channel blocker]] once used to treat [[Angina pectoris|angina]]. It is no longer sold in the United States. | '''Bepridil''' (trade name '''Vascor''') is a [[calcium channel blocker]] once used to treat [[Angina pectoris|angina]]. It is no longer sold in the United States. | ||
| Line 30: | Line 31: | ||
It has been implicated in causing ventricular arrhythmia ([[Torsade de pointes]]). | It has been implicated in causing ventricular arrhythmia ([[Torsade de pointes]]). | ||
==References== | |||
{{reflist|2}} | |||
==External | ==External Links== | ||
* {{MedlinePlusDrugInfo|medmaster|a697050}} | * {{MedlinePlusDrugInfo|medmaster|a697050}} | ||
{{Calcium channel blockers}} | {{Calcium channel blockers}} | ||
[[Category:Calcium channel blockers]] | [[Category:Calcium channel blockers]] | ||
[[Category:Cardiovascular Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drug]] | |||
[[Category: | |||
Latest revision as of 20:39, 23 July 2014
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | Well absorbed |
| Protein binding | 99% |
| Metabolism | Hepatic, CYP3A4-mediated |
| Elimination half-life | 42 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C24H34N2O |
| Molar mass | 421.02 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Bepridil (trade name Vascor) is a calcium channel blocker once used to treat angina. It is no longer sold in the United States.
It is nonselective.[1]
It has been discussed as a possible option in the treatment of atrial fibrillation.[2]
It has been implicated in causing ventricular arrhythmia (Torsade de pointes).
References
- ↑ Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
- ↑ Imai S, Saito F, Takase H; et al. (May 2008). "Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm". Circ. J. 72 (5): 709–15. doi:10.1253/circj.72.709. PMID 18441448.
External Links
Categories:
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Calcium channel blockers
- Cardiovascular Drugs
- Drug